Full description
This 12-week triple blind randomised controlled trial includes young people (15-25 years, 60% female) with moderate to severe major depressive disorder measured using the MADRS, recruited between 2013 and 2017 across Victoria, Australia. All participants received treatment as usual plus either aspirin (n = 40), rosuvastatin (n = 48) or placebo (n = 42) with assessments at baseline and weeks 4, 8, 12 and 26. Dataset includes primary outcome changes in the MADRS scale from baseline to 12 weeks, demographic information, suicidality, anxiety, substance use, and medication.Notes
HeSANDA 1.0.0User Contributed Tags
Login to tag this record with meaningful keywords to make it easier to discover
Identifiers
- DOI : 10.26187/E83M-V673